Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05022927 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma

StatusUnknown
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 5, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
  2. Trial status: Recruiting to Active, Not Recruiting Site details revised at 11 of 11 sitesv8 Show 1 more changeShow less
    • Site details revised at 11 of 11 sites
  3. Primary and study completion dates: Sep 30, 2024 to Dec 31, 2025 Primary endpoints: 18 to 23 · Enrollment target: 158 to 179 · Study sites: 8 to 11 · 2 morev7 Show 5 more changesShow less
    • Primary endpoints: 18 to 23
    • Enrollment target: 158 to 179
    • Study sites: 8 to 11
    • Secondary endpoints: 14 to 20
    • Study arms: 4 to 5

    See this version in full on ClinicalTrials.gov ↗

  4. Eligibility criteria revisedv6 See this version in full on ClinicalTrials.gov ↗
  5. Study sites: 7 to 8v5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 6 to 7v4
  2. Study sites: 4 to 6v3
  3. Study sites: 3 to 4v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Roche/Genentech
366 trials monitored
See 33 trials at risk
Liver Cancer
1,512 trials monitored
See 63 trials at risk
This is a multicenter, open-label, dose-escalation study designed to determine the maximum tolerated dose (MTD) by evaluating dose-limiting toxicities (DLTs) and to evaluate the safety, tolerability, pharmacokinetics, anti-tumor effect, and biomarkers of ERY974 in combination with atezolizumab and bevacizumab following premedication with tocilizumab in patients with locally advanced or metastatic HCC.
Trial Details
NCT Number NCT05022927
Lead Sponsor Chugai Pharmaceutical
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 179 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov